PAR-27-069: Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01)

PAR-27-069: Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01)

The PAR-27-069 X01 is a National Institutes of Health (NIH) Program Announcement that gives qualified teams access to stored All of Us biospecimens (blood serum, plasma, and/or extracted genomic DNA) and related participant-linked data context from the All of Us Research Program. It is unusual in that it is a resource access route, not a typical research grant with direct project funds. If your team wants to run high-quality molecular or integrated analyses on large existing cohorts through All of Us materials, this is a powerful lever for research leverage.

The opportunity was posted in 2026 with recurring due dates in 2026 and 2027, and is explicitly aimed at projects that can propose assays and data-generation plans at scale. The NOFO says these are X01 “resource access” awards and that no funds are provided by the announcement itself. That means the strongest applications typically include a realistic external funding plan while showing how All of Us access changes what is scientifically possible.

Quick reference: at-a-glance details

What this opportunity is (and is not)

What this is

PAR-27-069 is designed for teams who need access to high-value, pre-existing U.S.-scale biospecimen and linked data assets to run new molecular assays that generate data with broad reuse value. It is positioned around the All of Us mission: enable precision health breakthroughs using linked health, behavioral, environmental, and biological data.

Applications are expected to propose:

• projects that use stored biospecimens effectively and at scale
• assays with demonstrated validity
• plans that generate reusable datasets and analyses beyond the study-specific publication
• return-of-value plans to communicate outcomes back to participants in a meaningful way

This route is therefore best for investigators with an existing science question that depends on real biobank access and a feasible analytical pipeline.

What this is not

It is not a direct subsidy. The NOFO states clearly that X01 resource access announcements do not provide funds for proposal costs, staff time, assay work, shipping, or compute. It is also not a clinical trial mechanism. NIH reviewers are not looking for “small exploratory feasibility” in isolation; they are evaluating fit, scale, assay rigor, and use-case value against All of Us priorities.

A second important distinction: this is not a mechanism for unfunded exploratory applications. It expects you to secure or already have support from external sources and then use those resources in tandem with All of Us support structures.

Why teams still apply even without grant money

Teams often ask this first. The answer is practical: access itself is the central value proposition. This announcement lets you gain access to a uniquely governed, harmonized, very large sample and data environment under strict NIH and participant-protection rules. In contexts where recruitment costs, biospecimen handling, and high-throughput assay capacity are major bottlenecks, secure All of Us access can make a high-conviction analysis possible within existing external budget envelopes.

The upside is strongest for work that can’t be done with local cohorts alone. Examples in the NOFO’s priority language include:

• integrated multiomics frameworks
• biomarker discovery/validation
• early disease risk stratification
• therapeutic-response prediction
• large-cohort approaches that can produce broadly reusable outputs

In practical terms, if your team can articulate how All of Us cohort scope creates a materially different scientific design than a local clinical dataset, your competitiveness improves.

Eligibility and policy fit: who should apply

The NOFO’s eligible organization language is broad, including universities, nonprofit institutions, for-profit entities, governments, and certain other entity types. It also allows foreign organizations and foreign components of U.S. organizations to apply in appropriate forms, while drawing a strict limit around funded foreign subawards.

Important eligibility points from the notice:

• Clinical trials are not allowed.
• Foreign entities are generally allowed, but funded foreign subawards/subcontracts are not permitted in this NOFO pathway.
• Foreign collaborations can be part of project design if non-funded or structured consistently with NIH policy.
• Organizations and PI-level registrants must have required registrations complete before submission.

For many teams, the first real blocker is not scientific fit but compliance readiness. NIH registration can take weeks; missed setup causes avoidable late/noncompliant outcomes. The requirement stack is not optional:

• SAM/NCAGE as applicable
• eRA Commons (with PI/Signing Official details properly configured)
• Grants.gov identity registration
• ORCID linkage for PD(s)/PI(s) where required

The NOFO also flags registration timing explicitly: if your registrations are incomplete near deadline, that is not a valid excuse for late submission under electronic submission rules.

Funding and budget interpretation: why budget lines say $0

The source line for this X01 is explicit: it is a resource access mechanism. The NIH form instructions require entering $0 for federal and total requested funds. Because your actual scientific execution costs are likely nonzero, a compliant application still needs a robust funding strategy.

A solid approach is:

1. Split the narrative between access request and execution plan.
2. Document confirmed funding sources (awards, institutional funds, philanthropy, internal pilot pools).
3. Include a contingency plan if a pending award is delayed.
4. Map each budget-like need to evidence of support: staff time, biospecimen handling, data processing, compute costs, agreement administration, publication support, and return-of-value deliverables.

Because the NOFO explicitly allows a one-year window to secure funding after provisional support where needed, teams with active pending support still can be viable, but they should present this clearly and defensibly.

This is often a pass/fail threshold for reviewer confidence: an idea with excellent science but weak funding readiness is easily downgraded. You need to show this is not aspirational speculation.

What makes an application strong

The review structure follows NIH logic with criteria that map to common failure points. The NOFO’s X01-specific emphases are where teams win and lose.

Significance

Reviewers ask whether the proposed question advances precision medicine priorities and whether it is genuinely enabled by All of Us resources. Strong examples in successful narratives usually:

• frame a scientifically important problem tied to broad health relevance
• show why All of Us linked biobank+phenotype data adds value compared with standard cohorts
• explain biospecimen conservation and scientific yield trade-offs

A weak application on significance often sounds interesting but generic; strong work is specific about translational impact and why large-sample design is necessary.

Investigator team

The program expects at least one team member with practical All of Us Researcher Workbench fluency and ability to access Controlled Tier resources. They also expect demonstrated methodological competence to run the requested assay program at target scale. In practice, this means:

• PI has domain depth in the disease or mechanism area
• an analyst can handle compute pipeline, storage, quality assessment, and statistical power
• assay collaborators can run throughput workflows with reproducible QC

Innovation and approach

Applications that merely re-run known assays without clear new insight tend to be weaker than those that propose novel combinations, better-integrated endpoints, or stronger generalizability. The NOFO repeatedly requires clarity on:

• assay choice and rationale
• sample-size/power plans
• statistical analysis design and bias mitigation
• privacy and re-identification risk controls
• data quality/security architecture (including lab throughput readiness)

Projects proposing integrated analyses, multi-omic framing, and broad downstream applicability fit the “future-facing” spirit of the program.

Operational realism

This is the most frequently under-modeled section. The NOFO expects details about:

• biospecimen handling conditions
• requested volumes/masses and why those are minimum necessary
• assay lab capacity (including infrastructure and data capture systems)
• timeline from biospecimen request to final analyses
• explicit return of data to the All of Us platform and participant-facing return-of-value activities

A high-quality plan shows sequencing: cohort selection, sample request, QC, assay execution, data linkage, analysis, output release.

Application preparation roadmap

You can approach this in five controlled phases.

Phase 1: Build the scientific package first

Start by defining:

• the primary question
• why existing All of Us linked biospecimen context is necessary
• what novel scientific output will come out of the work
• target sample size and assay assumptions

Do this before touching system forms. If your question is not clearly tied to All of Us-specific assets, revise it now.

Phase 2: Map the data and sample strategy

Use the All of Us resources listed in the NOFO to identify whether eligible cohorts and required data features are present:

• biospecimen type (serum, plasma, genomic DNA)
• available phenotypes and records for targeted subgrouping
• long-term data integration value

Keep requests tightly scoped. The NOFO calls out unvalidated methods and overbroad sample requests as likely non-responsive. Justify each requested volume with assay design, assay sensitivity, and cohort power assumptions.

Phase 3: Build the operational readiness section

Prepare a short execution architecture:

• lab facilities and instrumentation capable of the planned throughput
• chain-of-custody, storage, and assay monitoring plan
• data governance and privacy controls for de-identified linked data
• lab and analysis team with clear role assignments

Where possible, include objective evidence: existing QC pipelines, prior assay scale experience, LIMS capabilities, and sample management procedures.

Phase 4: Build evidence of funding readiness

Because required fields in the NOFO call for evidence of funding or a concrete plan to obtain it, include:

• active grant references (if any)
• institutional commitment language
• collaborator letters for shared resources
• milestone-based spend plan tied to No-Fund status

Make the reviewer’s life easy: if this part is ambiguous, they infer risk and reduce confidence.

Phase 5: Compliance pass before submission

Use the official instructions checklist as a final gate:

• research strategy length and structure limits respected
• page limits and form field rules followed
• registration complete in SAM, ORCID, eRA Commons
• all team members aligned with registration roles
• submission route tested ahead of deadline

This is where many otherwise strong applications fail due to administrative errors.

Common mistakes to avoid

1. Submitting generic hypotheses: The NOFO favors clearly scoped, All of Us-enabled projects.
2. Underestimating method validation expectations: proposals must use validated assays, especially for large cohorts.
3. Confusing resource access with funded research: all project costs need external support.
4. Ignoring foreign collaboration limits: funded foreign subawards are not allowed under this route.
5. Skipping return-of-value planning: publication-only outcomes are not enough; outreach/participant-value language is required.
6. Inadequate sample justification: requesting excessive biospecimen volumes or poorly explained quantities appears weak.
7. Weak timeline realism: reviewers assess feasibility from sample request through analysis completion.
8. Assuming no clinical trial allowed means no human subject controls: human-subject study records and privacy safeguards remain essential where applicable.

Step-by-step timeline strategy for 2026/2027

The NOFO shows three application entry points:

• July 1, 2026 (new applications)
• October 30, 2026 (new and resubmissions)
• March 1, 2027 (new and resubmissions)

For teams entering late in the cycle, March 1, 2027 is usually the practical target, but still requires full readiness. A robust cycle plan:

• 6–8 weeks before target due date: finalize science/assay plan and secure letters.
• 4 weeks before: finalize funding evidence sections and external support narrative.
• 2 weeks before: complete draft forms, run cross-check of page limits.
• 1 week before: final registrations verification and submission dry run.
• Final 48 hours: targeted compliance review and correction.

A strong application often wins by being complete and specific, not by being last-minute novel.

Review and post-submission expectations

The NOFO’s review criteria are standard NIH review dimensions (significance, investigator quality, innovation, approach, environment), with extra emphasis on:

• demonstrated need and benefit of All of Us resource access
• assay validation and biospecimen/data security
• project-level funding viability
• return-of-value and data contribution plan

Expect at least two key filters after submission:

• compliance screening by CSRs and NIH components
• scientific and programmatic alignment review by relevant NIH stakeholders

Applications that are incomplete, noncompliant, or nonresponsive to resource-access requirements can be triaged out before substantive review.

FAQ (practical)

Does this provide money?

No. It provides access pathway value. NIH is clear that no budget is attached for the project.

Is this only for U.S. institutions?

Not only; the NOFO includes non-domestic entities, but with specific rules for funded cross-border arrangements.

Can we propose pilot projects?

Yes, if scientifically valid and sufficiently scalable for the framework and if sample design is appropriately justified. However, weakly justified small pilot framing is less likely to pass if it doesn’t meet the broad value bar.

Are clinical trials allowed?

No. Clinical-trial-style projects are not eligible.

What should we submit first if we are still fundraising?

Submit the strongest feasible All of Us-focused scientific plan and evidence of funding actions. The NOFO allows applicants who cannot yet fully fund the work to provide a plan to secure funding within one year of provisional support, but only when clearly credible.

Official resources and links

• Main opportunity text: https://files.simpler.grants.gov/opportunities/aae1388d-369b-4899-be47-2b34c587b623/attachments/58897ff4-836a-4ebd-8e31-7491c7494b42/PAR-27-069-Full-Announcement.html
• All of Us official program page: https://www.allofus.nih.gov/
• All of Us Researcher Workbench: https://www.researchallofus.org/
• All of Us X01 partnered studies resource: https://www.researchallofus.org/biospecimen-announcement/

Final positioning guidance

Treat this as a high-intensity technical bid, not a casual idea submission. The review process rewards teams that understand both science and operations. Emphasize three things in your draft:

1. Why All of Us materially changes the research question.
2. Why each requested assay/sample choice is minimal but sufficient.
3. Why your team can execute safely, securely, and on time with documented funding support.

If your team can answer all three without stretching assumptions, PAR-27-069 becomes one of the most leverage-efficient NIH routes available for biospecimen-driven discovery in 2026/2027.